Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.30 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9950358 | 0.83 | OPRK1 (0.32) | OPRK1 | |
| SCHEMBL9951344 | 0.80 | HCRTR2 (0.33) | KCNH2 | |
| SCHEMBL9950809 | 0.78 | — | — | |
| SCHEMBL10188802 | 0.75 | OPRK1 (0.36) | NPC1OPRM1SLC22A1SLC6A4ADRA1A | |
| SCHEMBL9950367 | 0.75 | OPRK1 (0.36) | NPC1OPRM1SLC22A1SLC6A4ADRA1A | |
| SCHEMBL10188807 | 0.74 | NPC1 (0.35) | NPC1OPRM1SLC22A1SLC6A4ADRA1A | |
| SCHEMBL9950559 | 0.74 | NPC1 (0.35) | NPC1OPRM1SLC22A1SLC6A4ADRA1A | |
| SCHEMBL9950351 | 0.73 | HCRTR2 (0.42) | OPRM1OPRD1KCNH2 | |
| SCHEMBL9950228 | 0.71 | HCRTR2 (0.55) | KCNH2 | |
| SCHEMBL10189120 | 0.70 | HCRTR2 (0.59) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | HCRTR2, HCRTR1, CNR1 | NPC1 710/4885OPRM1 57/4885SLC22A1 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.